Nautilus Biotechnology, Inc. – NASDAQ:NAUT

Add to watchlist

$0.68

-1.02

-60%

Market open

Closed in about 5 hours

-32.81%

month

-32.81%

quarter

-49.85%

year

Market Cap	210.94M
Enterprise value	261.47M

P/E	-6.02
EV/Sales	N/A
EV/EBITDA	-5.25
Price/Sales	N/A
Price/Book	1.09
PEG ratio	-0.25
EPS	-0.55

Revenue	N/A
EBITDA	-75.05M
Income	-67.44M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Profit margin
Jun 2023	0	-15.80M
Sep 2023	0	-15.87M
Dec 2023	8.21M	-17.02M	-207.31%
Mar 2024	0	-18.73M

Nautilus Biotechnology Financials Estimate

Q Y

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Analyst Estimates
Mar 2024	0	-18.73M
Sep 2025	4.5M	-26.24M	-583.26%
Oct 2025	3.3M	-25.86M	-783.69%
Dec 2025	8M	-25.02M	-312.84%

Analysts Price target
Financials & Ratios estimates

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Earnings per share (EPS)
2024-02-28	-0.16	-0.14
2024-04-30	-0.16	-0.00015

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Debt to assets
Jun 2023	330767000	41.09M	12.42%
Sep 2023	318336000	41.06M	12.9%
Dec 2023	305565000	40.21M	13.16%
Mar 2024	288650000	39.15M	13.57%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Cash Flow
Jun 2023	-13.54M	-2.25M	98K
Sep 2023	-11.73M	13.07M	16K
Dec 2023	-13.9M	-41.06M	253K
Mar 2024	-16.26M	22.35M	245K

Nautilus Biotechnology alternative data

Nautilus Biotechnology
Employees

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Employee count
Aug 2023	153
Sep 2023	153
Oct 2023	153
Nov 2023	153
Dec 2023	160
Jan 2024	160
Feb 2024	160
Mar 2024	167
Apr 2024	167
May 2024	167
Jun 2024	163
Jul 2024	163

Nautilus Biotechnology
Hedge Funds Holdings Q1 2023

18.54% -18.42%

of NAUT is owned by hedge funds

46 -32

hedge funds hold NAUT stock

23.09M -22.96M

shares is hold by hedge funds

NAUT hedge funds holdings changes

Nautilus Biotechnology
Insider Trading

Nautilus Biotechnology, Inc. (NASDAQ:NAUT): Insider trades (number of shares)
Period	Buy	Sel
Nov 2021	296978	0
Dec 2021	318022	0
Mar 2022	50000	0
May 2022	50000	0
Jun 2022	5500	0
Aug 2022	77500	0
Sep 2022	120000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	27 Sep 2022	SANKAR SUBRAMANIAN officer: Senior VP, Product Development officer: Senior VP, Product Dev..	Common Stock	5,000	$2.03	$10,150
Purchase	26 Sep 2022	SANKAR SUBRAMANIAN officer: Senior VP, Product Development officer: Senior VP, Product Dev..	Common Stock	10,000	$2.03	$20,250
Purchase	23 Sep 2022	WELD GWEN E officer: Chief People Officer officer: Chief People Officer	Common Stock	30,000	$2.03	$60,780
Purchase	16 Sep 2022	SANKAR SUBRAMANIAN officer: Senior VP, Product Development officer: Senior VP, Product Dev..	Common Stock	35,000	$2.16	$75,460
Purchase	15 Sep 2022	SANKAR SUBRAMANIAN officer: Senior VP, Product Development officer: Senior VP, Product Dev..	Common Stock	40,000	$2.19	$87,760
Purchase	19 Aug 2022	MOWRY ANNA officer: CFO and Treasurer officer: CFO and Treasurer	Common Stock	17,500	$2.3	$40,215
Purchase	15 Aug 2022	MURPHY MATTHEW B. officer: General Counsel officer: General Counsel	Common Stock	7,500	$2.84	$21,308
Purchase	12 Aug 2022	MURPHY MATTHEW B. officer: General Counsel officer: General Counsel	Common Stock	2,500	$2.85	$7,125
Purchase	8 Aug 2022	PATEL SUJAL M director, 10 perc..	Common Stock	8,346	$2.93	$24,445
Purchase	5 Aug 2022	PATEL SUJAL M director, 10 perc..	Common Stock	41,654	$2.92	$121,630

NAUT insider trading transactions

Nautilus Biotechnology
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 30 Apr 2024	Q1 2024 Earnings Call Transcript
Q4 2023 28 Feb 2024	Q4 2023 Earnings Call Transcript
Q3 2023 31 Oct 2023	Q3 2023 Earnings Call Transcript
Q2 2023 2 Aug 2023	Q2 2023 Earnings Call Transcript

NAUT earnings call transcripts

Nautilus Biotechnology
Executives

Insider	Age	Compensation
Mr. Sujal M. Patel (1975) Co-Founder, Chief Executive Officer, Pres, Sec. & Director	50	$251,450
Dr. Parag Mallick Ph.D. (1977) Chief Scientist & Director	48	$250,250
Dr. Subra Sankar Ph.D. (1959) Senior Vice President of Product Devel.	66	$38,470

Nautilus Biotechnology
Latest News

Thursday, 31 October 2024
08:00	Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy for Radiology and Biomedical Imaging Research's Distinguished Investigator Award	globenewswire.com
Wednesday, 30 October 2024
08:00	Nautilus Biotechnology to Participate in the Inaugural Guggenheim Healthcare Conference	globenewswire.com
Tuesday, 29 October 2024
13:17	Nautilus Biotechnology, Inc. (NAUT) Q3 2024 Earnings Call Transcript	seekingalpha.com
Tuesday, 30 July 2024
15:16	Nautilus Biotechnology, Inc. (NAUT) Q2 2024 Earnings Call Transcript	seekingalpha.com
08:00	Nautilus Biotechnology Reports Second Quarter 2024 Financial Results	globenewswire.com
Tuesday, 9 July 2024
08:00	Nautilus Biotechnology to Announce Second Quarter 2024 Financial Results on July 30, 2024	globenewswire.com
Friday, 3 May 2024
13:01	Nautilus Biotechnology (NAUT) Upgraded to Buy: Here's What You Should Know	Zacks Investment Research
Tuesday, 30 April 2024
13:19	Nautilus Biotechnology, Inc. (NAUT) Q1 2024 Earnings Call Transcript	Seeking Alpha
Wednesday, 28 February 2024
13:13	Nautilus Biotechnology, Inc. (NAUT) Q4 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 7 February 2024
08:00	Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024	GlobeNewsWire
Tuesday, 31 October 2023
11:22	Nautilus Biotechnology, Inc. (NAUT) Q3 2023 Earnings Call Transcript	Seeking Alpha
Wednesday, 11 October 2023
08:05	Nautilus Biotechnology to Announce Third Quarter Financial Results on October 31, 2023	GlobeNewsWire
Friday, 4 August 2023
08:00	Nautilus Biotechnology to Participate in Upcoming August Investor Conferences	GlobeNewsWire
Wednesday, 2 August 2023
13:33	Nautilus Biotechnology, Inc. (NAUT) Q2 2023 Earnings Call Transcript	Seeking Alpha
Tuesday, 11 July 2023
09:23	Nautilus Biotechnology to Announce Second Quarter Financial Results on August 2, 2023	GlobeNewsWire
Wednesday, 24 May 2023
08:05	Nautilus Biotechnology to Participate in Upcoming June Investor Conferences	GlobeNewsWire
Tuesday, 18 April 2023
16:05	Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023	GlobeNewsWire
Thursday, 23 March 2023
08:00	Nautilus Biotechnology to Participate in B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference	GlobeNewsWire
Friday, 17 March 2023
14:17	3 Penny Stocks Under $3 To Watch In March	PennyStocks
Saturday, 25 February 2023
15:09	Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript	Seeking Alpha
Thursday, 26 January 2023
08:00	Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023	GlobeNewsWire
Tuesday, 1 November 2022
14:35	Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript	Seeking Alpha
Tuesday, 30 August 2022
08:00	Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference	GlobeNewsWire
Tuesday, 2 August 2022
12:02	Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q2 2022 Results - Earnings Call Transcript	Seeking Alpha
Tuesday, 3 May 2022
12:21	Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q1 2022 Results - Earnings Call Transcript	Seeking Alpha
Thursday, 7 April 2022
08:00	Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022	GlobeNewsWire
Monday, 4 April 2022
08:00	Nautilus Biotechnology to Present at EuPA and AACR Meetings	GlobeNewsWire
Saturday, 26 February 2022
10:42	Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q4 2021 Results - Earnings Call Transcript	Seeking Alpha
Friday, 21 January 2022
20:11	Jim Cramer considers the investment cases for Nautilus Biotechnology and Cyxtera Technologies	CNBC Television
Friday, 7 January 2022
14:34	Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point	Seeking Alpha

Ideas & Opinions

Seeking Alpha 10 Mar 2023

Nautilus Biotechnology (NAUT) Investor Presentation - Slideshow
Seeking Alpha 7 Jan 2022

Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point

Frequently Asked Questions (FAQ)

What's the price of Nautilus Biotechnology stock today?

One share of Nautilus Biotechnology stock can currently be purchased for approximately $0.68.
When is Nautilus Biotechnology's next earnings date?

Unfortunately, Nautilus Biotechnology's (NAUT) next earnings date is currently unknown.
Does Nautilus Biotechnology pay dividends?

No, Nautilus Biotechnology does not pay dividends.
How much money does Nautilus Biotechnology make?

Nautilus Biotechnology has a market capitalization of 210.94M. Nautilus Biotechnology made a loss 63.68M US dollars in net income (profit) last year or -$0 on an earnings per share basis.
What is Nautilus Biotechnology's stock symbol?

Nautilus Biotechnology, Inc. is traded on the NASDAQ under the ticker symbol "NAUT".
What is Nautilus Biotechnology's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Nautilus Biotechnology?

Shares of Nautilus Biotechnology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Nautilus Biotechnology's key executives?
Nautilus Biotechnology's management team includes the following people:
- Mr. Sujal M. Patel Co-Founder, Chief Executive Officer, Pres, Sec. & Director(age: 50, pay: $251,450)
- Dr. Parag Mallick Ph.D. Chief Scientist & Director(age: 48, pay: $250,250)
- Dr. Subra Sankar Ph.D. Senior Vice President of Product Devel.(age: 66, pay: $38,470)
Is Nautilus Biotechnology founder-led company?

Yes, Nautilus Biotechnology is a company led by its founder Mr. Sujal M. Patel.
How many employees does Nautilus Biotechnology have?

As Jul 2024, Nautilus Biotechnology employs 163 workers, which is 2% less then previous quarter.
When Nautilus Biotechnology went public?

Nautilus Biotechnology, Inc. is publicly traded company for more then 5 years since IPO on 7 Aug 2020.
What is Nautilus Biotechnology's official website?

The official website for Nautilus Biotechnology is nautilus.bio.
Where are Nautilus Biotechnology's headquarters?

Nautilus Biotechnology is headquartered at 2701 Eastlake Avenue East, Seattle, WA.
How can i contact Nautilus Biotechnology?

Nautilus Biotechnology's mailing address is 2701 Eastlake Avenue East, Seattle, WA and company can be reached via phone at +20 63 332001.

Nautilus Biotechnology, Inc.

nautilus.bio

Exchange:

NASDAQ

Full time employees:

161

Industry:

Biotechnology

Sector:

Healthcare

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

+20 63 332001

2701 Eastlake Avenue East
Seattle, WA 98102

CIK: 0001808805
ISIN: US63909J1088
CUSIP: 63909J108